CHRS
Coherus Oncology, Inc.NASDAQHealthcare$1.73-0.57%ClosedMarket Cap: $202.7M
As of 2026-04-06
Valuation
P/E (TTM)
1.21
PEG
0.00
P/B
3.29
P/S
4.64
EV/EBITDA
-0.86
DCF Value
$-0.27
FCF Yield
-70.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.2%
Operating Margin
-429.5%
Net Margin
398.4%
ROE
789.4%
ROA
65.0%
ROIC
-153.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $12.7M | 68.3% | $-45.9M | $-37.6M | $-0.31 | — |
| FY 2025 | $42.2M | 67.2% | $-181.1M | $-170.3M | $-1.45 | — |
| Q3 2025 | $11.6M | 67.8% | $-44.3M | $-35.5M | $-0.30 | — |
| Q2 2025 | $10.3M | 66.9% | $-45.5M | $297.8M | $-0.39 | — |
| Q1 2025 | $7.6M | 65.1% | $-45.4M | $-56.6M | $-0.49 | — |
| Q4 2024 | $54.1M | 37.5% | $-42.2M | $-50.7M | $-0.44 | — |
| FY 2024 | $267.0M | 56.0% | $-111.7M | $28.5M | $0.25 | — |
| Q3 2024 | $70.8M | 70.7% | $-6.4M | $-10.8M | $-0.09 | — |
| Q2 2024 | $65.0M | 54.5% | $-20.5M | $-12.9M | $-0.11 | — |
| Q1 2024 | $2.3M | 37.7% | $-67.8M | $102.9M | $0.82 | — |
| Q4 2023 | $91.5M | 7.6% | $-68.9M | $-79.7M | $-0.71 | — |
| FY 2023 | $257.2M | 38.2% | $-203.2M | $-237.9M | $-2.53 | — |